Cargando…

Correction: Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines

Detalles Bibliográficos
Autores principales:	Jennings, Barbara A., Loke, Yoon K., Skinner, Jane, Keane, Melanie, Chu, Gavin S., Turner, Richard, Epurescu, Daniel, Barrett, Ann, Willis, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395435/ https://www.ncbi.nlm.nih.gov/pubmed/25876069 http://dx.doi.org/10.1371/journal.pone.0124893

Ejemplares similares

Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines
por: Jennings, Barbara A., et al.
Publicado: (2013)

Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe
por: Afolabi, Boluwatife Lawrence, et al.
Publicado: (2023)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
por: Martens, Forike K., et al.
Publicado: (2020)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
por: Arrigoni, Elena, et al.
Publicado: (2017)

A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy
por: Del Re, Marzia, et al.
Publicado: (2014)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
por: Wigle, Theodore J., et al.
Publicado: (2021)

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients
por: Del Re, Marzia, et al.
Publicado: (2015)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
por: Reynolds, Gavin P
Publicado: (2012)

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

Effects of pharmacogenetic profiles on pediatric pain relief and adverse events with ibuprofen and oxycodone
por: Ali, Samina, et al.
Publicado: (2023)

Genetic selection? A study of individual variation in the enzymes of folate metabolism
por: Jennings, Barbara A, et al.
Publicado: (2010)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer
por: Traylor, Matthew, et al.
Publicado: (2018)

Pharmacogenetics to Avoid Adverse Drug Reactions
por: López-Fernández, Luis A.
Publicado: (2022)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
por: Ruzzo, A, et al.
Publicado: (2017)

Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients
por: Mo, Xianwei, et al.
Publicado: (2020)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

Antituberculosis Drug‐Induced Adverse Events in the Liver, Kidneys, and Blood: Clinical Profiles and Pharmacogenetic Predictors
por: Hu, Xuejiao, et al.
Publicado: (2017)

Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study
por: de Miguel, Laura, et al.
Publicado: (2023)

Pharmacogenetics of pediatric acute lymphoblastic leukemia in Uruguay: adverse events related to induction phase drugs
por: Burgueño-Rodríguez, Gabriela, et al.
Publicado: (2023)

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
por: García-Alfonso, P., et al.
Publicado: (2021)

A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer
por: Chan, Jason, et al.
Publicado: (2013)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
por: Negarandeh, Reza, et al.
Publicado: (2020)

Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
por: Reynolds, Gavin P.
Publicado: (2012)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
por: García-González, Xandra, et al.
Publicado: (2021)

Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents
por: Mattishent, Katharina, et al.
Publicado: (2021)

Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
por: Jurczyk, Michał, et al.
Publicado: (2021)

Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy
por: Korver, Samantha K., et al.
Publicado: (2023)

Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics
por: Piatkov, Irina, et al.
Publicado: (2012)

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
por: Chang, Chih-Jung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o7t75esl28cdgopg8t9bott1tc